3.4 Management of Multidrug-Resistant Organisms & High-Consequence Pathogens

3.4 Management of Multidrug-Resistant Organisms & High-Consequence Pathogens

The emergence and dissemination of Multidrug-Resistant Organisms (MDROs) and High-Consequence Pathogens represent critical challenges for infection preventionists. MDROs are defined as microorganisms—primarily bacteria and fungi—that are resistant to one or more classes of antimicrobial agents. Controlling MDROs requires aggressive containment protocols to prevent endemicity and healthcare facility transmission.

---

Core MDRO Containment Strategies

Facilities employ a comprehensive hierarchy of interventions to control MDRO spread:

1. Administrative Support & Stewardship: Antimicrobial stewardship programs (ASPs) to eliminate unnecessary broad-spectrum antibiotic pressure, which drives selective drug resistance.
2. Active Surveillance Testing (AST): Targeted screening of high-risk patient populations upon admission (e.g., ICU admissions, transfers from long-term care facilities) to detect asymptomatic reservoirs.
3. Contact Isolation & Cohorting: Prompt isolation of colonized or infected patients. Placing patients in single rooms or cohorting patients infected with identical strains.
4. Environmental Decontamination: Rigorous daily and terminal cleaning using EPA-registered disinfectants effective against specific targeted pathogens.
5. Inter-Facility Communication: Standardized transfer forms notifying receiving healthcare facilities of a patient’s MDRO colonization/infection status.

---

Targeted MDRO Pathogen Protocols

1. Methicillin-Resistant Staphylococcus aureus (MRSA)

• Mechanism: Resistance mediated by the mecA or mecC gene encoding an altered penicillin-binding protein (PBP2a), which has low affinity for beta-lactam antibiotics.
• Surveillance Site: Anterior nares swab.
• Decolonization Protocol: Targeted pre-operative or ICU decolonization using topical nasal mupirocin 2% ointment applied twice daily combined with daily chlorhexidine gluconate (CHG) 4% skin cleansing baths for 5 days.

2. Vancomycin-Resistant Enterococcus (VRE)

• Mechanism: Resistance mediated by vanA or vanB gene clusters modifying peptidoglycan cell wall precursors (D-Ala-D-Ala to D-Ala-D-Lac).
• Surveillance Site: Perirectal swab or stool sample.
• Environmental Control: VRE survives for extended periods on inanimate surfaces. Strict adherence to Contact Precautions and routine cleaning with EPA-registered hospital disinfectants.

3. Carbapenem-Resistant Enterobacterales (CRE)

• Mechanism: Production of carbapenemase enzymes (e.g., Klebsiella pneumoniae carbapenemase [KPC], New Delhi metallo-beta-lactamase [NDM], OXA-48) that hydrolyze carbapenems and all beta-lactams.
• Surveillance Site: Perirectal/stool swab.
• Containment Protocol: Immediate single-room Contact Precautions, dedicated nursing staff (minimizing staff overlap between CRE-positive and uninfected patients), AST screening of epidemiologically linked roommates, and notification of local public health authorities.

4. Candida auris

• Clinical Significance: An emerging, highly resistant fungal yeast causing severe bloodstream and wound infections. C. auris causes high mortality, persists on patient skin and environmental surfaces for months, and exhibits frequent misidentification on conventional automated laboratory systems.
• Surveillance Site: Composite bilateral axilla and groin swab.
• Environmental Disinfection: CRITICAL EXAM POINT: C. auris is resistant to standard quaternary ammonium compound (QAC) disinfectants. Facilities MUST use EPA-registered disinfectants from List P or List K (sporicidal agents such as sodium hypochlorite/bleach or hydrogen peroxide formulations).

---

Discontinuation of Isolation Precautions for MDROs

Indefinite isolation can lead to negative patient outcomes (e.g., decreased nurse contact time, depression). However, discontinuing precautions prematurely risks outbreak re-emergence. CDC outlines stringent clearance criteria:

• General Rule: Isolation should remain in place for the duration of the inpatient stay for high-consequence MDROs (CRE, C. auris).
• VRE & MRSA Clearance Criteria: Requires meeting all of the following:
  1. Resolution of clinical signs and symptoms of infection.
  2. A minimum of 3 consecutive negative surveillance cultures collected at least 24 hours apart.
  3. All clearance cultures must be obtained off active anti-infective therapy (antimicrobials targeting the organism must be discontinued at least 48 hours to 1 week prior to culture collection).

---

High-Consequence Pathogens (Ebola & Viral Hemorrhagic Fevers)

Viral Hemorrhagic Fevers (VHFs), such as Ebola, Marburg, and Lassa viruses, are Category A bioterrorism agents and high-consequence pathogens that demand specialized containment protocols.

Facility & PPE Containment Protocols

• Tiered Hospital Readiness: Frontline Healthcare Facilities (identify/isolate/inform), Assessment Hospitals, and Designated VHF Treatment Centers.
• Isolation Environment: AIIR with negative pressure, private bathroom, and dedicated anteroom for PPE donning and doffing.
• PPE Specifications (Zero Skin Exposure):
  • Powered Air-Purifying Respirator (PAPR) with full hood/head cover OR full-face shield with N95 respirator.
  • Impermeable fluid-resistant coverall with integrated hood or boot covers.
  • Double gloving with extended cuff examination gloves.
  • Waterproof apron if vomiting or diarrhea is present.
• Trained Observer Protocol: A designated, trained monitor MUST utilize a checklist to observe and verbally guide every step of donning and doffing to ensure zero protocol breaches.
• Waste Management: All solid waste generated during care of a VHF patient is classified as Category A infectious substance requiring dedicated on-site autoclaving or specialized incineration by licensed hazardous waste handlers.

---

Pathogen Disinfection, Surveillance & Isolation Matrix